Eurofins · 21 hours ago
ELISA Scientist – Analytical Development
Eurofins is an international life sciences company focused on analytical testing services across various industries. The ELISA Scientist role involves executing analytical methods for biologic therapeutic product release and characterization, ensuring compliance with regulatory standards.
BiotechnologyGeneticsHealth CareLife SciencePharmaceutical
Responsibilities
Independently perform routine ELISA-based assays and other plate-based methods (e.g., potency, activity, HCP, qPCR) using established protocols
Document and present results in accordance with cGMP/GLP and regulatory requirements
Apply independent judgment in method selection, troubleshooting, and data analysis for moderately complex problems
Maintain laboratory equipment and ensure general lab upkeep
Occasionally support non-lab tasks and weekend cell passage work as needed
Qualification
Required
Bachelor's degree in Cell & Molecular Biology, Biochemistry, or related field with 2+ years of hands-on ELISA experience
Strong understanding of plate-based assays (binding ELISA, cell-based potency) and their application in biologics testing
Proficiency with assay troubleshooting and software tools such as SoftMax Pro and PLA; flow cytometry experience is a plus
Ability to multitask, maintain accurate records, and comply with company policies
Excellent communication, organizational skills, and attention to detail
Must be authorized to work in the U.S. without restriction or sponsorship
Preferred
Master's degree is a plus; demonstrated ELISA expertise through thesis or publications preferred
Benefits
Comprehensive medical coverage, dental, and vision options
Life and disability insurance
401(k) with company match
Paid vacation and holiday
Yearly goal-based bonus & eligibility for merit-based increases
Company
Eurofins
Eurofins provides testing and support services to the pharmaceutical, food, environmental, and consumer products industries.
Funding
Current Stage
Public CompanyTotal Funding
$1.05B2025-06-26Post Ipo Debt· $586.37M
2025-03-27Post Ipo Debt· $431.4M
2021-10-22Grant· $30M
Recent News
2025-12-16
Business Wire
2025-12-08
Company data provided by crunchbase